This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
302
1000mg iv daily
750mg iv q 23h for 3-14 days
1500mg iv q 12h for 3-14 days
Clinical cure rate\n\n
Time frame: End of study visit (7-10 days after end of treatment)
Adverse events, vital signs, laboratory parameters\n
Time frame: Throughout study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
New Orleans, Louisiana, United States
Unnamed facility
Shreveport, Louisiana, United States
Unnamed facility
Detroit, Michigan, United States
Unnamed facility
Butte, Montana, United States
Unnamed facility
Holmdel, New Jersey, United States
Unnamed facility
Winston-Salem, North Carolina, United States
Unnamed facility
Buenos Aires, Argentina
Unnamed facility
Buenos Aires, Argentina
Unnamed facility
Buenos Aires, Argentina
Unnamed facility
Buenos Aires, Argentina
...and 39 more locations